Actinogen Medical Limited (ASX: ACW), a biotechnology company developing novel therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol, has announced the completion of its options underwriting. The company, which is currently focused on its lead compound Xanamem The post Actinogen Medical Completes Options Underwriting, Securing $4.77 Million in Funding first appeared on Sharecafe .
Actinogen Medical Limited (ASX: ACW), a biotechnology company developing novel therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol, has announced the completion of its options underwriting. The company, which is currently focused on its lead compound Xanamem The post Actinogen Medical Completes Options Underwriting, Securing $4.77 Million in Funding first appeared on Sharecafe .This article was originally published by Share Cafe.
Read Full Story on Source Site →
